[1]
Gardiner, P.; Graham, R.E.; Legedza, A.T.R.; Eisenberg, D.M.; Phillips, R.S. Factors associated with dietary supplement use among prescription medication users. Arch. Intern. Med., 2006, 166(18), 1968-1974.
[2]
Bent, S. Herbal medicine in the United States: Review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. J. Gen. Intern. Med., 2008, 23(6), 854-859.
[3]
Brantley, S.J.; Argikar, A.A.; Lin, Y.S.; Nagar, S.; Paine, M.F. Herb-drug interactions: challenges and opportunities for improved predictions. Drug Metab. Dispos., 2014, 42(3), 301-317.
[4]
Tyler, S.K.K.; Eckl, V.; Morton, C.; Stredney, R. Herbal supplement sales in US increase 7.7% in 2016. HerbalGram, 2017, 115, 56-65.
[5]
Scripture, C.D.; Figg, W.D. Drug interactions in cancer therapy. Nat. Rev. Cancer, 2006, 6(7), 546-558.
[6]
Dresser, G.K.; Bailey, D.G. A basic conceptual and practical over-view of interactions with highly prescribed drugs. Can. J. Clin. Pharmacol., 2002, 9(4), 191-198.
[7]
Holmes, R.S.; Cox, L.A.; VandeBerg, J.L. Mammalian carboxy- lesterase 3: Comparative genomics and proteomics. Genetica, 2010, 138(7), 695-708.
[8]
Satoh, T.; Hosokawa, M. The mammalian carboxylesterases: from molecules to functions. Annu. Rev. Pharmacol. Toxicol., 1998, 38, 257-288.
[9]
Hosokawa, M.; Furihata, T.; Yaginuma, Y.; Yamamoto, N.; Koy-ano, N.; Fujii, A.; Nagahara, Y.; Satoh, T.; Chiba, K. Genomic structure and transcriptional regulation of the rat, mouse, and human carboxylesterase genes. Drug Metab. Rev., 2007, 39(1), 1-15.
[10]
Hosokawa, M. Structure and catalytic properties of carboxyles- terase isozymes involved in metabolic activation of prodrugs. Molecules, 2008, 13(2), 412-431.
[11]
Satoh, T.; Hosokawa, M. Structure, function and regulation of carboxylesterases. Chem. Biol. Interact., 2006, 162(3), 195-211.
[12]
Imai, T.; Hosokawa, M. Prodrug approach using carboxylesterases activity: Catalytic properties and gene regulation of carboxyles- terase in mammalian tissue. J. Pestic. Sci., 2010, 35(3), 229-239.
[13]
Laizure, S.C.; Herring, V.; Hu, Z.; Witbrodt, K.; Parker, R.B. The role of human carboxylesterases in drug metabolism: Have we over-looked their importance? Pharmacotherapy, 2013, 33(2), 210-222.
[14]
Sprouse, A.A.; Van Breemen, R.B. Pharmacokinetic interactions between drugs and botanical dietary supplements. Drug Metab. Dispos., 2016, 44(2), 162-171.
[15]
Chen, F.; Wen, Q.; Jiang, J.; Li, H.L.; Tan, Y.F.; Li, Y.H.; Zeng, N.K. Could the gut microbiota reconcile the oral bioavailability conundrum of traditional herbs? J. Ethnopharmacol., 2016, 179, 253-264.
[16]
Sun, D.X.; Ge, G.B.; Dong, P.P.; Cao, Y.F.; Fu, Z.W.; Ran, R.X.; Wu, X.; Zhang, Y.Y.; Hua, H.M.; Zhao, Z.; Fang, Z.Z. Inhibition behavior of Fructus Psoraleae’s ingredients towards human carboxyl-esterase 1 (hCES1). Xenobiotica, 2016, 46(6), 503-510.
[17]
Li, Y.G.; Hou, J.; Li, S.Y.; Lv, X.; Ning, J.; Wang, P.; Liu, Z.M.; Ge, G.B.; Ren, J.Y.; Yang, L. Fructus Psoraleae contains natural compounds with potent inhibitory effects towards human carboxyl-esterase 2. Fitoterapia, 2015, 101, 99-106.
[18]
Liu, Y.J.; Li, S.Y.; Hou, J.; Liu, Y.F.; Wang, D.D.; Jiang, Y.S.; Ge, G.B.; Liang, X.M.; Yang, L. Identification and characterization of naturally occurring inhibitors against human carboxylesterase 2 in White Mulberry Root-bark. Fitoterapia, 2016, 115, 57-63.
[19]
Wang, A.H.; Huo, X.K.; Feng, L.; Sun, C.P.; Deng, S.; Zhang, H.L.; Zhang, B.J.; Ma, X.C.; Jia, J.M.; Wang, C. Phenolic glycosides and monoterpenoids from the roots of Euphorbia ebracteolata and their bioactivities. Fitoterapia, 2017, 121, 175-182.
[20]
Mai, Z.P.; Zhou, K.; Ge, G.B.; Wang, C.; Huo, X.K.; Dong, P.P.; Deng, S.; Zhang, B.J.; Zhang, H.L.; Huang, S.S.; Ma, X.C. Protostane triterpenoids from the rhizome of alisma orientale exhibit inhibitory effects on human carboxylesterase 2. J. Nat. Prod., 2015, 78(10), 2372-2380.
[21]
Zou, L.W.; Li, Y.G.; Wang, P.; Zhou, K.; Hou, J.; Jin, Q.; Hao, D.C.; Ge, G.B.; Yang, L. Design, synthesis, and structure-activity relationship study of glycyrrhetinic acid derivatives as potent and selective inhibitors against human carboxylesterase 2. Eur. J. Med. Chem., 2016, 112, 280-288.
[22]
Zou, L.W.; Dou, T.Y.; Wang, P.; Lei, W.; Weng, Z.M.; Hou, J.; Wang, D.D.; Fan, Y.M.; Zhang, W.D.; Ge, G.B.; Yang, L. Structure-activity relationships of pentacyclic triterpenoids as potent and selective inhibitors against human carboxylesterase 1. Front. Pharmacol., 2017, 8, 435.
[23]
Yuan, W.J.; Ding, X.; Wang, Z.; Yang, B.J.; Li, X.N.; Zhang, Y.; Chen, D.Z.; Li, S.L.; Chen, Q.; Di, Y.T.; Aisa, H.A.; Hao, X.J. Two novel diterpenoid heterodimers, bisebracteolasins A and B, from euphorbia ebracteolata hayata, and the cancer chemotherapeutic potential of bisebracteolasin A. Sci. Rep., 2017, 7(1), 14507.
[24]
Hatfield, M.J.; Tsurkan, L.G.; Hyatt, J.L.; Edwards, C.C.; Lemoff, A.; Jeffries, C.; Yan, B.; Potter, P.M. Modulation of esterified drug metabolism by tanshinones from Salvia miltiorrhiza (“Danshen”). J. Nat. Prod., 2013, 76(1), 36-44.
[25]
Lee, J.H.; Shin, Y.J.; Kim, H.J.; Oh, J.H.; Jang, Y.P.; Lee, Y.J. Danshen extract does not alter pharmacokinetics of docetaxel and clopidogrel, reflecting its negligible potential in P-glycoprotein and cytochrome P4503A-mediated herb-drug interactions. Int. J. Pharm., 2011, 410(1-2), 68-74.
[26]
Crow, J.A.; Herring, K.L.; Xie, S.; Borazjani, A.; Potter, P.M.; Ross, M.K. Inhibition of carboxylesterase activity of THP1 mono- cytes/macrophages and recombinant human carboxylesterase 1 by oxysterols and fatty acids. Biochim. Biophys. Acta, 2010, 1801(1), 31-41.
[27]
Xu, J.; Yin, L.; Xu, Y.; Li, Y.; Zalzala, M.; Cheng, G.; Zhang, Y. Hepatic carboxylesterase 1 is induced by glucose and regulates postprandial glucose levels. PLoS One, 2014, 9(10), e109663.
[28]
Chen, Y.T.; Shi, D.; Yang, D.; Yan, B. Antioxidant sulforaphane and sensitizer trinitrobenzene sulfonate induce carboxylesterase-1 through a novel element transactivated by nuclear factor-E2 related factor-2. Biochem. Pharmacol., 2012, 84(6), 864-871.
[29]
Fahey, J.W.; Wade, K.L.; Wehage, S.L.; Holtzclaw, W.D.; Liu, H.; Talalay, P.; Fuchs, E.; Stephenson, K.K. Stabilized sulforaphane for clinical use: Phytochemical delivery efficiency. Mol. Nutr. Food Res., 2017, 61(4), 1600766.
[30]
Liu, R.; Tam, T.W.; Mao, J.; Saleem, A.; Krantis, A.; Arnason, J.T.; Foster, B.C. The effect of natural health products and traditional medicines on the activity of human hepatic microsomal- mediated metabolism of oseltamivir. J. Pharm. Pharm. Sci., 2010, 13(1), 43-55.
[31]
Gorman, G.S.; Coward, L.; Darby, A.; Rasberry, B. Effects of herbal supplements on the bioactivation of chemotherapeutic agents. J. Pharm. Pharmacol., 2013, 65(7), 1014-1025.
[32]
Trana, C.; Toth, G.; Wijns, W.; Barbato, E.St. John’s Wort in patients non-responders to clopidogrel undergoing percutaneous coronary intervention: A single-center randomized open-label trial (St. John’s Trial). J. Cardiovasc. Transl. Res., 2013, 6(3), 411-414.
[33]
Lau, W.C.; Welch, T.D.; Shields, T.; Rubenfire, M.; Tantry, U.S.; Gurbel, P.A. The effect of St John’s Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. J. Cardiovasc. Pharmacol., 2011, 57(1), 86-93.
[34]
Liu, A.C.; Zhao, L.X.; Lou, H.X. Curcumin alters the pharmacokinetics of warfarin and clopidogrel in Wistar rats but has no effect on anticoagulation or antiplatelet aggregation. Planta Med., 2013, 79(11), 971-977.
[35]
Yang, M.S.; Law, F.C.; Wong, R.N.; Mak, N.K.; Wei, X.Y. Interaction between oseltamivir and herbal medicines used for treating avian influenza. Hong Kong Med. J., 2012, 18(Suppl. 6), 34-36.
[36]
Guan, H.Y.; Li, P.F.; Wang, X.M.; Yue, J.J.; He, Y.; Luo, X.M.; Su, M.F.; Liao, S.G.; Shi, Y. Shengjiang Xiexin decoction alters pharmacokinetics of irinotecan by regulating metabolic enzymes and transporters: A multi-target therapy for alleviating the gas- trointestinal toxicity. Front. Pharmacol., 2017, 8, 769.
[37]
Rodriguez-Mateos, A.; Vauzour, D.; Krueger, C.G.; Shanmuga-nayagam, D.; Reed, J.; Calani, L.; Mena, P.; Del Rio, D.; Crozier, A. Bioavailability, bioactivity and impact on health of dietary flavonoids and related compounds: An update. Arch. Toxicol., 2014, 88(10), 1803-1853.
[38]
Yu, K.; Chen, F.; Li, C. Absorption, disposition, and pharmacoki- netics of saponins from Chinese medicinal herbs: what do we know and what do we need to know more? Curr. Drug Metab., 2012, 13(5), 577-598.
[39]
Bachmann, K.A. Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions: pitfalls, progress and promise. Curr. Drug Metab., 2006, 7(1), 1-14.
[40]
Wang, X.; Wang, G.; Shi, J.; Aa, J.; Comas, R.; Liang, Y.; Zhu, H.J. CES1 genetic variation affects the activation of angiotensin- converting enzyme inhibitors. Pharmacogenomics J., 2016, 16(3), 220-230.
96
6
1
1